Share
2,068 Posts.
lightbulb Created with Sketch. 305
clock Created with Sketch. 15/03/19
12:01
Share
Originally posted by jazzapat:
↑
hi Chris, I don’t think the antibiotic dosing for the second phase III trial is the issue. This trial design was agreed with the FDA and supports the claim for the prevention of recurrent BV. E.g. the antibiotics treated the BV and vivagel prevented recurance in a population who suffered from rBV. Primary and secondary points all met. This supports the claim for prevention after treatment.
Expand
With your summary jazzapat you suggest that antibiotics is part of the treatment regime whereas it has always been claimed by SPL that they are dispensing with the need to use them.
